Here's Why Investors May Bet on BioMarin (BMRN) Stock Now

BioMarin Pharmaceutical Inc. (BMRN) develops treatments for serious life-threatening medical conditions, mainly affecting children. The company’s top line is currently being driven by strong demand for its marketed products, especially new dwarfism drug, Voxzogo. Also, the recent approval of Roctavian (valoctocogene roxaparvovec, or valrox), a gene therapy for treating adults with severe hemophilia A, has opened up a key sales opportunity.BioMarin has an attractive early-stage pipeline primarily focusing on ...